Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019
We describe common side effects of this treatment, and advise how they are best prevented and managed.
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Immunotherapy | Kidney Cancer | Neoadjuvant Therapy | Renal Cell Carcinoma | Toxicology | Urology & Nephrology